HemoHub Focus Group (April 9th)
We started our meeting with a focus group on the subject of HemoHub™, a specialized Middleware dedicated to the hemostasis portfolio of instruments of Werfen. The focus group reflected the main drivers of the value of HemoHub by showing different examples of success stories from European Affiliates.
Werfen France with the help of Morgane Razafimahatratra, Product Manager IT Solutions, shared one success story from a Hospital in the east of France, Mulhouse, where HemoHub allowed Werfen France to be very competitive during the tender phase. Once Werfen won in this account, the customer implemented several rules for automatic validation including complex rules that involve patient history, patient treatments, biases, and automated algorithms. These rules had a significant impact on the workflow of the Laboratory with a reduction of 90% of the time the Laboratory spends on technical validation, in addition to the reduction of the time spent on quality management of reports that are now centralized and automatically managed and stored by HemoHub.
The French experience was followed by the Italian experience and Silvio Castagni, Group Product Manager Hemostasis, shared three examples of success stories across Italy. The first success story was related to a multisite hospital and the benefit of standardization of processes across several sites, standardization of the validation and processing of problematic samples with the ability to review centrally the curves and HIL profiles of samples. The second success story was related to the benefits of HemoHub as the intelligent data manager of our HemoCell™ solution having the ability to manage all the information that the instrument and the track can share to send the sample to the optimal instrument to be processed. These features are in addition to the features that HemoHub is able to provide in a standalone situation of standardization, centralization, and automation of processes, reports, and validation. The third success story was related to the integration of other instruments of our portfolio (Rotem® and AcuStar®) to connect the value of expertise in Hemostasis between the Lab and the Point of Care.
The Focus Group continued with a hands-on activity with several specialized stations of value drivers of HemoHub. Four stations were available: QC management, Patient and Document Management, KPIs and Statistics, and Validation Rules that allowed the participants to experience first-hand the software and its capabilities. We wrapped up the focus group by looking at the Sales Process and the planning required to have a successful installation of HemoHub from promotional material to tender specifications to installation requirements.
General Hemostasis Marketing Session (April 10th)
We opened the day with a general Hemostasis Update, focusing on a business review of the performance of Werfen as a group, of EEMEAI and more specifically Hemostasis. This was followed by an update on instruments, reagents and the Hemostasis IT Solutions.
This was followed by Remo Tazzi, Worldwide Marketing Director Hemostasis, who shared several updates regarding competition and how Werfen was positioned in comparison by focusing on 5 points, Market Position, Instruments, Reagents, IT solutions and Lab Automation to emphasize our very strong competitive position versus Stago, Roche, Siemens, and Sysmex. The competitive position of the company was illustrated in a case simulation where 5 groups developed a solution based on an assessment of the problems of a customer and against one main competitor (Stago, Roche, Siemens) and shared it with the rest of the teams.
In the afternoon, we went through 3 additional chapters of specialization. The first was HemoCell, our Hemostasis automation workcell and we reviewed an example of financial assessment of opportunities of HemoCell and a success story in Switzerland with the first HemoCell installation in EEMEAI, an experience of successful collaboration copresented by Valeria De Luca, Key Account Manager Hemostasis, and Raffael Frei, Head of Sales Axonlab.
The second was Chemiluminescence and AcuStar, where we reviewed the value drivers of the technology and what are the new tests that will be launched on the platform with the clinical implications associated with the testing. This was followed with a Greek success story with the AcuStar instrument shared by Nikolaos Simos, Product and Account Manager Antisel.
We finished the day with the third chapter of specialization related to Hemostasis Diagnosis Management that focused on sharing Knowledge, Information, and Decision making across different departments and specialties to improve patient care, experience, and outcome by leveraging our IT Solution like HemoHub and our educational tools that span from webinars, to our educational platform Werfen Academy to our scientific events like the 11th Advanced Hemostasis Seminar that will take place in Bucharest Romania on October 1st and 2nd followed by a HemoHub Promotional day on October 3rd.
These days would not be possible without the contribution of Gianpaolo Pozzato, Stefano Fialà, Valeria De Luca, Silvio Castagni, Morgane Razafimahatratra, Remo Tazzi, Raffael Frei, Nikolaos Simos and all the participants in the meeting.
Thank you all!
Hemostasis Team